Search 

“AdeTherapeutics’ approach has potential to become standard of care,” says Dr. Greenberg, Vice Chair Obs & Gyn at Brigham and Women’s Hospital and Associate Professor at Harvard Medical School.

Our platform technology which KOL’s have pointed out as a game changer in the area of preventing post operative fibrosis, is poised to create significant value.  The pipeline contains a phase II drug for prevention of post operative fibrosis following pelvic and abdominal surgeries, med devices (collaboration with DSM Biomedical) for spinal surgery and additional opportunities in orthopedics.  

The Company has built a world class team, utilized a capital efficient, highly targeted and focused approach and brought on the necessary strategic partners to bring first-in-class products to the market and establish standard of care for millions of surgeries worldwide.Key value propositions:

•             useful in more procedures than current medical devices

•             significant higher efficacy vs market comparators

•             attractive safety profile & accelerated regulatory pathway

Key Milestones achieved:

• Phase II trial started
• Key markets patents issued: USA, EU, Japan
• Efficacy shown in different tissues areas
• Two peer reviewed publications in 2014

Advent Life Sciences

We invest predominantly in early and mid-stage life sciences companies.  We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.

Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.

Real people. Real insight. Real value.

Innovation. Clarity. Execution.

ALIAD is the venture capital subsidiary of the Air Liquide Group (L'Air Liquide S.A.), one of the largest multinational providers of industrial and medical gases and related activities, headquartered in Paris, France. The healthcare division of the Air Liquide Group has been playing a significant role in healthcare with over €2 billion in revenue. 
ALIAD aims to promote the Group’s growth and access to innovations through taking minority stakes in innovative technology start-ups outside the Group. ALIAD can lead or co-invest with other investors. Typical allocations are made in equity and range from €1-10 million. ALIAD is currently seeking new opportunities across a wide geography, including Western Europe, North and South America and Asia.

Allurion Technologies was founded in 2009 to develop an intragastric balloon for weight loss that can be administered without surgery, endoscopy, or anesthesia. Obesity is a worldwide epidemic, yet only 2% of patients who qualify for bariatric surgery go on to be treated. Several endoscopic weight loss techniques are under development for the overweight and obese population, but they are restricted to the gastroenterologist call point and more expensive due to the costs associated with endoscopy and anesthesia.

Allurion's Elipse intragastric balloon is swallowed and excreted and can be delivered without endoscopy or anesthesia, thereby making it accessible to non-endoscopists and to consumers at a lower price point.

Allurion is currently a clinical-stage company seeking funds for further clinical work and OUS commercialization.

Antibody Solutions is a premier developer of therapeutic, diagnostic and critical reagent antibodies. Our platforms include human antibodies from transgenic OmniRats™, Hybridoma Libraries™, and high-throughput flow-cytometry screening of cell-associated targets. We provide full technical support and project management with all services performed in the USA. 

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.